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ABSTRACT AND KEYWORDS 
 
Background and purpose  
 
The Gi-coupled, ADP-activated P2Y12 receptor is well characterised as playing a key role in 
platelet activation via crosstalk with P2Y1 in ADP-evoked intracellular Ca
2+ response. There 
is limited knowledge on the role of P2Y12 in ADP-evoked Ca
2+ responses in other blood cells.  
Here we investigate the role of P2Y12 receptor activation in modulation of ADP-evoked Ca
2+ 
responses in human THP-1 monocytic cells.  
 
 
Experimental approach 
 
A combination of intracellular Ca2+ measurements, RT-PCR, immunocytochemistry, 
leukocyte isolation and siRNA-mediated gene knockdown were used to identify the role of 
P2Y12 receptor activation.  
 
Key results 
 
ADP-evoked intracellular Ca2+ responses (EC50 2.7 M) in THP-1 cells were abolished by 
inhibition of phospholipase C (U73122) or sarco/endoplasmic reticulum Ca2+-ATPase 
(thapsigargin).  Loss of ADP-evoked Ca2+ responses following treatment with MRS2578 (IC50 
200 nM) revealed a major role for P2Y6 in mediating ADP-evoked Ca
2+ responses.  ADP-
evoked responses were attenuated either with pertussis toxin treatment, or P2Y12 inhibition 
with two chemically distinct antagonists (ticagrelor, IC50 5.3 M; PSB-0739, IC50 5.6M).  
ADP-evoked responses were suppressed following siRNA-mediated P2Y12 gene 
knockdown.  The inhibitory effects of P2Y12 antagonists were fully reversed following 
adenylate cyclase inhibition (SQ22536).  P2Y12 receptor expression was confirmed in freshly 
isolated human CD14+ monocytes.      
 
Conclusion and implications   
 
Taken together, these data suggest that P2Y12 activation positively regulates P2Y6-mediated 
intracellular Ca2+ signalling through suppression of adenylate cyclase activity in human 
monocytic cells. 
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INTRODUCTION 
 
The adenine nucleotide ADP serves as an important signalling molecule that is implicated in 
processes such as platelet aggregation (Dorsam and Kunapuli, 2004) and immune 
modulation (Ben Addi et al., 2010). ADP binds to P2Y1, P2Y6, P2Y12 and P2Y13, which are 
members of the G protein-coupled P2Y receptor family. Activation of Gq-coupled P2Y1 and 
P2Y6 causes downstream IP3 generation via PLC-mediated breakdown of PIP2, and 
subsequent calcium ion (Ca2+) release through endoplasmic reticulum IP3 receptors (Erb and 
Weisman, 2012). Conversely, P2Y12 and P2Y13 are Gi-coupled and hence inhibit production 
of cAMP and stimulate PI3K when activated (Erb and Weisman, 2012).  
 
Platelet aggregation in response to ADP is one of the earliest examples of extracellular 
nucleotide signalling. It is firmly established that ADP activates platelets via the P2Y1 and 
P2Y12 receptors, and the functionality of both receptors is required for normal platelet 
aggregation (Jin and Kunapuli, 1998). The emergence of P2Y12 as a vital component in ADP-
evoked platelet activation has led to the development of anti-platelet drugs targeting this 
receptor, such as ticagrelor and clopidogrel. The rise in cytosolic Ca2+ in response to ADP is 
deemed responsible for the ADP-mediated activation of platelets (Dorsam and Kunapuli, 
2004). Although P2Y12 is Gi-coupled and should therefore not cause intracellular Ca
2+ 
mobilisation, outcomes from a previous study suggest that P2Y12 potentiates the Gq P2Y1-
mediated Ca2+ response to ADP in a cross-talk mechanism (Hardy et al., 2004). Hardy et al. 
(2004) propose that P2Y12 mediates inhibition of adenylate cyclase and activation of PI3K, 
which collectively positively modulates the Ca2+ signal induced by ADP. The same P2Y1-
P2Y12 crosstalk mechanism described in platelets by Hardy et al. (2004) was also suggested 
to be present in glioma C6 cells (Suplat et al., 2007).  
 
The role of P2Y12 in cells other than platelets is not well described, although recent evidence 
is promising. Findings by West et al. (2014) indicate a role for vessel wall P2Y12 in early 
atherogenesis, rather than platelet P2Y12. In addition to cardiovascular disease, P2Y12 has 
potentially been implicated in immune responses to ADP in macrophages (Zhang et al., 
2016) and dendritic cells (Ben Addi et al., 2010) in functions such as antigen uptake and 
chemotaxis. Therefore, non-platelet roles for P2Y12 have been suggested and should be 
further investigated. 
 
Monocytes are essential immune cells that, together with their progeny, facilitate innate 
immune defence via phagocytosis and cytokine production, but also activate the adaptive 
immune system through antigen uptake and presentation (Ziegler-Heitbrock, 2006). In this 
study, we apply the THP-1 monocytic cell line as an experimental model to investigate the 
expression of P2Y12 and the contribution of the receptor in ADP-evoked Ca
2+ responses, 
exploring the signal transduction mechanisms involved. As there have been no publications 
reporting a role for P2Y12 in monocytes, this investigation reveals a new role for P2Y12 in 
non-platelet Ca2+ responses, and contributes to our understanding of how monocytes 
function in health and disease.  
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MATERIALS AND METHODS  
 
Chemicals and reagents 
Unless otherwise stated, all chemicals and reagents were purchased from Sigma-Aldrich, 
with the exception of pertussis toxin and SQ22536 (Tocris). All chemicals (agonists and 
antagonists) were diluted using physiological saline (SBS buffer) (containing (mM): NaCl, 
130; KCl, 5; MgCl2, 1.2; CaCl2, 1.5; D-glucose, 8; HEPES, 10; pH 7.4) with the exception of 
CCL2 (SBS buffer containing 1%(w/v) bovine serum albumin), MRS2578, SQ22536 and 
ticagrelor (SBS buffer containing 1% (v/v) DMSO).  
 
Isolation of CD14+ human monocytes 
Peripheral blood mononucleated cells (PBMCs) were isolated from the blood of human 
volunteers using Histopaque-1077 (Sigma-Aldrich). CD14+ monocytes were magnetically 
labelled from a PBMC suspension using MACS CD14 MicroBeads (Miltenyi Biotec), and 
positively selected for via the MACS Cell Separation Column (Miltenyi Biotec) together with 
the QuadroMACS Separator (Miltenyi Biotec).  
 
Intracellular Ca2+ measurements & drug treatments 
1 x 106 THP-1 cells/mL were loaded for 1 h with 2 μM fura-2 AM in SBS buffer plus 0.01% 
(w/v) pluronic acid at 37°C. Cells were then pelleted and washed using SBS and plated at a 
density of 2x105 cells/well. The plated cells were allowed to settle for 1 hour at 37°C, during 
which stage antagonists were added 30 minutes into the hour, unless otherwise stated. 
Measurements were taken at 37°C using the FlexStation 3 instrument (Molecular Devices) 
measuring fura-2 fluorescence (340 nm excitation when Ca2+-bound; 380 nm excitation 
when unbound; 510 nm emission) at intervals of 2 seconds giving.  For all Ca2+ experiments, 
the signal reported is ‘F ratio’, the ratio between Fura-2 emission at 510 when excited at 340 
and 380nm.  For hexokinase-treated of ADP stocks, 1mM ADP in SBS solution was treated 
for 1 hour at 37C with 3 U/mL hexokinase from Saccharomyces cerevisiae (Sigma) prior to 
agonist application.   
 
Cell culture 
Cells from the THP-1 cell line were cultured at 37°C, 5% CO2 in RPMI 1640 medium 
containing 2 mM L-glutamine and supplemented with 10% (v/v) foetal bovine serum (FBS), 
50 IU/mL penicillin and 50 μg/mL streptomycin. Cells were maintained at a density between 
1 x 105 and 1 x 106 cells/mL.  
 
siRNA-mediated gene knockdown 
THP-1 cells (2 x 105 final amount) were incubated overnight in complete RPMI (10% FBS) 
without antibiotic before cells were transfected using Dharmacon siRNA (25 nM final 
concentration) via DharmaFECT 2 transfection reagent (obtained from Dharmacon 
Research, Inc.) using the manufacturer’s protocol in 96-well format.  
 
RNA extraction & RT-PCR 
 
Total RNA was extracted from THP-1 cells and CD14+ monocytes using Tri reagent (Sigma 
Aldrich) with a subsequent DNase I treatment (Ambion).  Complementary DNA was 
synthesised from 1 µg of total RNA using Superscript II reverse transcriptase (Invitrogen).  
PCR was performed using a Taq polymerase readymix (Sigma Aldrich) using primer pairs 
designed using the following sequences (accession numbers): P2RY1 - 
GTTCAATTTGGCTCTGGCCG (5’-3’), TTTTGTTTTTGCGGACCCCG (3’-5’) (NM_002563); 
P2RY6 - GCTCTCACTGTCATCGGCTT (5’-3’), TCTGCCATTTGGCTGTGAGT (3’-5’) 
(NM_176798); P2RY12 - ACTGGGAACAGGACCACTGA (5’-3’), 
CAGAATTGGGGCACTTCAGC (3’-5’) (NM_022788); P2RY13 - 
TTCCCAGCCCTCTACACAGT (5’-3’), GGCCCCTTTAAGGAAGCACA (3’-5’) (NM_176894). 
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Immunocytochemistry  
 
THP-1 cells adhered to glass coverslips were washed twice in phosphate-buffered saline 
(PBS) followed by fixative with 4%(w/v) paraformaldehyde.  Cells were permeabilised with 
0.25%(v/v) triton X-100 for 10 minutes followed by blocking with 1%(w/v) bovine serum 
albumin (BSA) for 30 minutes at room temperature.  Primary and secondary antibodies were 
diluted in PBS containing 1%(w/v) BSA and incubated with cells overnight a 4OC and for 1 
hour at room temperature, respectively.  Cells were mounted in Vectashield containing 
nucleus counterstain (4',6-diamidino-2-phenylindole; DAPI).  Goat polyclonal anti-P2Y12 
(Santa Cruz Biotechnology Inc) was used with Alexa 488-conjugated rabbit anti-goat 
(Abcam).  Rabbit polyclonal anti-P2Y1, anti-P2Y6 and anti-P2Y13 (Alomone) were used with 
Alexa 488-conjugated goat anti-rabbit (Invitrogen).  Cell imaging was performed using a 
laser-scanning Zeiss LSM510 Meta confocal microscope. 
 
Transmigration assays 
 
Transwell migration assay were perfomed as previously described (Sivaramakrishnan et al., 
2012; Campwala et al., 2014).  Briefly, assays were performed in 24-well plates using 
polyethylene terephthalate (PET) membrane transwell inserts with 3 m pores.  1x106 THP-1 
cells in RPMI (no serum) with vehicle or drug treatment were added to the upper chamber, 
and 3 M ADP or vehicle added to the lower chamber.  Assays were performed for 2 hours 
at 37C, and migrated cells counted on the underside of the transwell support using crystal 
violet staining.  Chemotaxic index was calculated as the ration of cells that migrated to ADP 
over vehicle control. 
 
Data analysis 
 
Data analysis was performed using Origin Pro 9.0 software (Origin Lab, USA). Dose–
response curves were fitted assuming a Hill coefficient of 1, with the Hill equation used to 
determine the degree of ligand-receptor cooperation. Figure data points represent mean 
values ± standard error of the mean (error bars). Statistical significance was determined 
using paired Student t-tests. Each point in the dose-response plots represents the average 
of the peak Ca2+ response. A confidence interval of 5% (P<0.05) is used throughout for 
statement of significance. 
 
Dose-response relationships were fitted using the equation of the hill equation:  
 
 
             
          
               
           
 
 
  
Nomenclature of Targets and Ligands  
 
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS 
Guide to PHARMACOLOGY (Harding et al., 2018), and are permanently archived in the 
Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017). 
 
 
RESULTS 
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ADP-evoked intracellular Ca2+ responses are mediated by P2Y6 receptor activation and 
modulated by Gi-dependent signalling 
 
ADP evoked concentration-dependent increases in intracellular Ca2+ with a half-maximal 
concentration of 2.7±0.3 μM (N=5) (Figures 1A and 1B).  Responses to maximal ADP 
concentrations were abolished following either phospholipase C inhibitor treatment (U73122) 
(Figure 1C) or calcium depletion of the ER store (thapsigargin) (Figure 1D).  Study by 
Mahaut-Smith et al (2000) identified that commercially available ADP contains some ATP.  
To exclude any contribution of trace ATP to ADP-evoked Ca2+ responses ADP stocks were 
treated with hexokinase.  Ca2+ response evoked by treated ADP were similar to untreated 
ADP, with a half-maximal concentration of 2.2 ±0.5 μM (N=5) (P>0.05 versus untreated 
ADP).   
 
P2Y6 antagonism by MRS2578 inhibited the ADP response almost completely with a half-
maximal concentration of 200±20 nM (N=3) (Figures 1E and 1F).  MRS2578 inhibited the 
ADP response in a non-competitive fashion (Figure 1G), consistent with the reported mode 
of antagonism at P2Y6 (Mamedova et al., 2004) and with previous findings 
(Sivaramakrishnan et al., 2012; Campwala et al., 2014).  Selective inhibition of P2Y1 with 
MRS2500 (tested up to 10 μM) (Figure 1H) or P2Y13 with MRS2211 (tested up to 10 μM) 
(Figure 1I) had no significant effect of ADP evoked Ca2+ responses. In addition to a 
dependency of phospholipase C activity and release of ER Ca2+ stores, we investigated the 
effect of Gi-dependent signalling by using Bordetella pertussis toxin (PTx).  PTx treatment (5 
nM, 3 hours) caused a significant attenuation of ADP-evoked intracellular Ca2+ response 
(Figure 2A), significantly suppressing the maximal response by approximately 30% and the 
half-maximal concentration for ADP (EC50 1.9±0.3 μM vs 2.9±0.2 μM with PTx; p<0.05, N=5) 
(Figures 2B).  In control experiments, CCL2-evoked Ca2+ responses were abolished by PTx 
treatment (Figure 2C), in agreement with our previous observations.  Together these 
findings suggest that ADP-evoked Ca2+ responses are mediated via P2Y6 activation and 
release of ER Ca2+, and that Gi-dependent signalling either constitutively or following ADP 
activation, positively modulates the ADP-evoked response. 
 
We next determined the expression of ADP receptors in THP-1 cells in an effort to probe 
further the molecular basis of ADP-evoked Ca2+ responses and identify receptors that may 
modulate them. RT-PCR analysis of P2Y receptors activated by ADP (Erb and Weisman, 
2012; Communi et al., 1996) in THP-1 cells revealed expression of P2Y1, P2Y6, P2Y12 and 
P2Y13 (Figure 3A). P2Y12 receptor mRNA expression was confirmed in freshly isolated 
CD14+ monocytes (Figure 3B).  P2Y1, P2Y6, P2Y12 and P2Y13 protein expression was 
confirmed by immunocytochemistry and confocal microscopy (Figure 3C). 
 
Effect of P2Y12 antagonism and knockdown on ADP-evoked Ca
2+ responses in THP-1 cells 
 
Of the ADP receptors expressed by THP-1 monocytes, P2Y12 is a known Gi-coupled 
receptor.  The role of P2Y12 activation during ADP challenge was investigated using PSB-
0739, a high affinity competitive antagonist (Baqi et., 2009), and ticagrelor, a P2Y12 
antagonist used clinically as an anti-thrombotic agent (Husted et al., 2006). Ticagrelor 
inhibited ADP-evoked Ca2+ responses in THP-1 cells in a concentration-dependent fashion 
(Figure 4A).  Ticagrelor inhibited ADP-evoked Ca2+ responses with a half-maximal 
concentration of 4.7±1.8 μM (N=5) and a non-competitive mode of action (Figures 4B and 
4C).  This is consistent with the observations of van Giezen et al (2009) where ticagrelor 
binds to P2Y12 at a site distinct from that of ADP, producing a non-competitive inhibition of 
ADP-induced aggregation in human platelets.  PSB-0739 inhibited ADP-evoked Ca2+ 
responses with a half-maximal concentration of 5.4±1.8 μM (N=5) (Figures 4D and 4E) and 
caused a rightward parallel shift in the ADP concentration-response curve (Figure 4F).  
Inhibition of the ADP response was approximately 80% at the highest concentrations of 
PSB-0739 tested.  Several studies have suggested that ticagrelor produces cardiovascular 
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benefit through a pleiotropic inhibition of the equilibrative nucleoside transporter 1 (ENT-1) 
(Aungraheeta et al., 2016), and a consequent elevation in extracellular adenosine.  To rule 
out this mechanism of action in THP-1 cells, we inhibited ENT-1 using 3μM 6-S-[(4-
nitrophenyl)methyl]-6-thioinosine (NBMPR), but observed no effect on ADP-evoked Ca2+ 
responses (data not shown).  Next, we undertook a gene knockdown strategy to support our 
observations with P2Y12 receptor antagonists.  siRNA targeting of P2Y12 or control gene 
GADPH achieved approximately 40% mRNA knockdown versus scrambled siRNA control 
cells.  ADP-evoked Ca2+ responses were attenuated by approximately 30% in cells with 
P2Y12 knockdown versus either GADPH knockdown or scrambled control cells (Figures 4G 
and 4H).  To investigate the biological relevance of P2Y12 receptor inhibition in THP-1s, we 
assays transmigration in response to ADP.  In these experiments, ADP stimulated significant 
THP-1 transmigration over a 2 hour period over vehicle (Figure 4I).  Addition of either 
ticagrelor or PSB-0739 attenuated cell migration to ADP (Figure 4I).  Together these data 
reveal that P2Y12 receptor activity is functional important for the generation of ADP evoked 
intracellular Ca2+ responses and migration in THP-1 cells. 
 
Adenylate cyclase inhibition reverses antagonistic effect of ticagrelor 
 
We hypothesised that the molecular mechanism underlying the positive contribution of P2Y12 
receptor to ADP-evoked Ca2+ responses could be due to a number of possibilities.  Firstly, 
that P2Y12 is solely Gi-coupled and its activity positively regulates P2Y6-mediated Ca
2+ 
signalling through classical suppression of adenylate cyclase, or secondly that P2Y12 can 
directly elicit a Ca2+ response, either through promiscuous Gq coupling or via Gi-coupling that 
directly elicits Ca2+ signalling through activation of atypical phospholipase C, a for signalling 
on the CCL2-CCR2 axis (Myers et al., 1995).  To explore this further, we investigated the 
requirement of adenylate cyclase activity for mediating the inhibitory action of ticagrelor.  
Adenylate cyclase inhibition with 300M SQ22536 had no effect on ADP-evoked Ca2+ 
responses (Figure 5A). However, SQ22536 could reverse the effect of ticagrelor, restoring 
the ADP concentration-response relationship and maximum response (Fmax = 3.32 ± 0.26 for 
ADP + 5 µM ticagrelor + 300 µM SQ22536; Fmax = 2.64 ± 0.21, ADP + 5 µM ticagrelor; Fmax = 
1.06 ± 0.10; N=5. The Fmax for ADP + 5 µM ticagrelor vs. ADP + vehicle control is 
significantly different to P<0.05) (Figures 5B and 5C). 
 
DISCUSSION 
 
Demonstrated in this study are novel findings identifying a role for P2Y12 in regulating 
intracellular Ca2+ signalling in non-platelet cells.  We have utilised THP-1 cells, a model used 
extensively to investigate human monocyte function, to demonstrate a functional role for 
P2Y12.  In addition, we identify P2Y12 expression in human CD14
+ monocytes.  There have 
been no published reports on the expression of P2Y12 in monocytes thus far, however the 
involvement of P2Y12 function in macrophage was investigated by Kronlage et al (2010).  
Stimulation of P2Y12 in macrophage was found to induce cell spreading with formation of 
lamellipodia, and inhibition of multiple purinergic receptors, including P2Y12, attenuated 
chemotaxis (Kronlage et al., 2010).  The signal transduction mechanisms downstream of 
P2Y12 were not investigated in this study.  P2Y12 receptor expression has also been reported 
in glial cells, smooth muscle and endothelium (Cattaneo, 2007). 
 
In this study, we demonstrate that ADP evokes intracellular Ca2+ signalling via P2Y6 receptor 
activation.  P2Y6 is often considered as the metabotropic receptor for UDP.  Though UDP is 
a more potent agonist at the human P2Y6 receptor by several orders of magnitude, ADP is a 
full agonist with a half-maximal concentration for inositol 1,4,5-triphosphate production in the 
micromolar range (Communi et al., 1996).  ADP is an important signalling cue in 
monocyte/macrophage biology. For example, in the same cell-line used in this investigation, 
THP-1, ADP stimulation caused release of the cytokine tumour necrosis factor alpha (TNF-
α) (Mattana et al., 2002). TNF-α release causes an inflammatory innate immune response 
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including immune cell recruitment. In addition, ADP has been shown in this investigation to 
induce calcium signals in THP-1 cells, and calcium signalling in circulating monocytes has in 
fact been suggested to result in the development of mature dendritic cells (Czerniecki et al., 
1997). Such examples indicate that ADP contributes to monocyte function, with specific 
reference to immune responses and differentiation.  ADP released from E. coli-infected 
mice, and from macrophages exposed to lipopolysaccharide (LPS), protected mice from E. 
coli-induced peritonitis via macrophage recruitment (Zhang et al., 2016). Additionally, ADP 
caused production of CCL2, a crucial chemokine in immune cell recruitment, which 
accordingly attracted more macrophages in a transwell assay (Zhang et al., 2016). Inhibition 
of downstream P2Y12 signalling, or macrophage P2Y12 deficiency, blocked immune 
responses to ADP, in turn allowing more bacteria to persist in infected mice (Zhang et al., 
2016). This investigation by Zhang et al. revealed that upon sensing danger, macrophages 
release ADP, which binds to receptors such as P2Y12, mediating actions such as chemokine 
release and consequent recruitment of immune cells.  Such findings may implicate ADP and 
P2Y12 as being crucial in forming a comprehensive immune response to infectious disease.  
 
It was discovered in platelets by Hardy et al. (2004) that the selective pharmacological P2Y12 
inhibitor AR-C69931MX partially blocked the calcium response to 10 μM ADP, which was 
also shown to be completely abolished by selective P2Y1 inhibition. This suggested that 
P2Y12 is able to positively modulate the P2Y1-mediated calcium response to ADP in 
platelets. Subsequently, Hardy et al. identified that the PI3K inhibitor LY294002 (10 μM) 
partially inhibited the P2Y12-dependent part of the calcium response to ADP. Moreover, the 
adenylate cyclase inhibitor SQ22536 partially restored ADP-evoked calcium responses in 
the presence of the P2Y12 inhibitor AR-C69931MX (Hardy et al., 2004). Taken together, 
these findings by Hardy et al. indicated in platelets that P2Y12 regulates P2Y1-mediated 
calcium responses to ADP through activation of PI3K and inhibition of adenylate cyclase.  
The findings in this investigation suggest that, of the ADP-activated P2Y receptors, ADP-
induced calcium responses in THP-1 cells are dependent on P2Y12 and P2Y6 activation, but 
not dependent on P2Y1 or P2Y13. Therefore, the basic principle identified reported by Hardy 
et al. is supported here for THP-1 monocytic cells, only with P2Y6 acting as the equivalent of 
P2Y1.  
  
Of interest is the observation that adenylate cyclase inhibition with SQ22536 on ADP-evoked 
Ca2+ signals in the absence of P2Y12 antagonism.  This data suggests adenylate cyclase 
activity does not exert a suppressive effect when P2Y6 and P2Y12 concurrently activated by 
ADP.  There are mechanistic explanations that could explain this observation.  For example, 
there may be no net change in adenylate cyclase activity upon ADP challenge due to co-
activation of a Gi-dependent pathway, mediated by P2Y12, and a Gs-dependent pathway 
mediated by another ADP receptor or possible adenosine receptor.  A predominance of Gs 
signaling could be revealed following P2Y12 inhibition, and increased adenylate cyclase 
activity suppresses ADP-evoked Ca2+ signaling.  Previous reports (Communi et al., 1997) 
have highlighted promiscuity for Gs and Gq coupling by P2Y11 which is expressed by THP-1 
cells (unpublished data).  However, P2Y11 is ATP activated and not activated by ADP at 
concentrations used in this study (Communi et al., 1997).  
 
How might P2Y12 regulate P2Y6-dependent signaling via adenylate cyclase? Firstly, this is 
unlikely to involve PKA-dependent phosphorylation of the P2Y6 receptor or receptor 
desensitization.  Compared to other P2Y receptors, such as P2Y4, P2Y6 display limited 
reduction in cell surface receptor number even in the presence of maximal agonist 
concentrations (Brinson & Harden, 2000).  There are no consensus PKA phosphorylation 
sites in the cytoplasmic loops of P2Y6, though this cannot discount PKA phosphorylation of 
an auxillary protein that positively regulates P2Y6 activity. 
 
There is currently much interest in the biological effects of P2Y12 antagonists beyond 
platelets (Nylander & Schultz, 2016).  Although further work is required to investigate the role 
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of P2Y12 in freshly isolated human monocytes, this work suggests that physiological and 
pharmacological modulation of P2Y12 can influence ADP-evoked intracellular Ca
2+ signalling 
in THP-1 cells and perhaps monocytes, which will likely influence key monocyte functionality 
such as migration, adhesion and cytokine production. 
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Figure 1 P2Y6 mediates ADP-evoked intracellular Ca
2+ responses in THP-1 cells. (A) 
Averaged (N=5) intracellular Ca2+ response evoked by ADP (30M). (B) Concentration-
dependency of ADP-evoked responses (EC50 2.70.3M; N=5).  Abolition of responses 
evoked by 30M ADP in control conditions (closed circles) or following pre-incubation (open 
circles) with 5M U73122 (C) or 1 M Thapsigargin (D); N=5 for both.  (E) ADP 
concentration response curve in the absence (closed circles) and presence (open circles) of 
300nM MRS2578 (N=5).  (F) Concentration-inhibition curve for P2Y6 antagonist MRS2578 
on intracellular Ca2+ response evoked by ADP (3M; N=5).  (G)  ADP concentration 
response curve in the absence (closed circles) and presence (open circles) of 300nM 
MRS2578 (N=5).  (H and I) Averaged (N=5) intracellular Ca2+ responses evoked by 3M 
ADP in the presence of vehicle (closed circles) or in the presence of P2Y1 antagonist 1M 
MRS2500 (H; open circles) or P2Y13 antagonist 10M MRS2211 (I; open circles).  For all 
experiments, F ratio is the ratiometric measurement of intracellular Ca2+ using fura-2. * 
p<0.05 
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Figure 2 Pertussis toxin attenuates ADP-evoked intracellular Ca2+ responses in THP-1 
cells. (A) Averaged (N=5) intracellular Ca2+ response evoked by ADP (3M) in the absence 
(closed circles) and presence (open circles) of 5nM pertussis toxin (3 hr pre-incubation). (B) 
ADP concentration-response relationship in absence (closed circles) and presence (open 
circles) of 5nM pertussis toxin (N=5). (C) Positive control showing abolition of control CCL2-
evoked response (closed circle) by 5nM pertussis toxin (open circles) (N=5).  Responses 
evoked by 50ng/mL CCL2.  For all experiments, F ratio is the ratiometric measurement of 
intracellular Ca2+ using fura-2. * p<0.05. 
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Figure 3 Expression of ADP-activated P2Y receptors in THP-1 cells.  (A) RT-PCR 
analysis of P2Y1 (326 bp), P2Y6 (391 bp), P2Y12 (698 bp) and P2Y13 (461 bp) expression in 
THP-1 monocytes.  RT-PCR analysis of P2Y12 (698) expression in freshly isolated CD14
+ 
monocytes from human peripheral blood.  For (A) and (B): predicted PCR ampilicon size 
given in parentheses; no RT (no reverse transcriptase) denotes negative control 
experiments for genomic DNA contamination. (C) Representative confocal microscopy 
images showing P2Y primary antibody immunoreactivity in fixed THP-1 cells.  Cells are 
labelled with polyclonal antibodies against P2Y receptor subunits and fluorescence (green) 
visualised by using a AF488-conjugated secondary antibody (lefthand panels).  Control is 
representative of an experiment where primary antibodies have been omitted.  Cells are 
counterstained with diamidino-2-phenylindole to identify nuclei (blue; in overlay in righthand 
panel).  Scale bar is 5m.  Experiments are representative of at least 3 independent 
experiments. 
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Figure 4 Effect of P2Y12 receptor antagonism and gene knockdown on ADP-evoked 
intracellular Ca2+ responses in THP-1 cells. (A) Averaged (N=5) ADP-evoked Ca2+ 
response in the absence (closed circles) and presence (open circles) of 3M ticagrelor. (B) 
Ticagrelor concentration-inhibition curve (IC50 4.71.8M; N=5) for responses evoked by 
3M ADP.  (C)  ADP concentration-response curve (N=5) in the presence of vehicle (closed 
circles) or 0.1 (open circles), 1 (closed squares) and 5M ticagrelor (open squares).  (D) 
Averaged (N=5) ADP-evoked Ca2+ response in the absence (closed circles) and presence 
(open circles) of 25M PSB-0739.  (E) PSB-0739 concentration-inhibition curve (IC50 
5.41.8M; N=5) for responses evoked by 3M ADP. (F)  ADP concentration response 
curve (N=4) in the presence of vehicle (closed circles) or 5 (open circles) and 10M PSB-
0739 (closed triangles). (G)  Effect of siRNA-mediated silencing of P2Y12 on ADP-evoked 
Ca2+ responses.  Averaged (N=5) Ca2+ responses evoked by 3M ADP in THP-1 cells 
following siRNA-mediated mRNA knockdown of P2Y12 (open circles) or GAPDH (closed 
squares) compared to cells transfected with scrambled siRNA (closed circles) (N=5).  (H) 
Bar chart showing effect of different siRNA treatment on peak Ca2+ responses evoked by 
3M ADP (N=5).  Responses in panels G and H are normalised to the magnitude of Ca2+ 
response elicited by 100 M ionomycin to control for cell number.  For all experiments, F 
ratio is the ratiometric measurement of intracellular Ca2+ using fura-2.  * p<0.05 (I) P2Y12 
antagonists attenuate THP-1 transwell migration towards ADP.  Chemotactic indexes 
comparing cell movement over 2 hours in control conditions (vehicle), 3M ADP alone or in 
the presence of either ticagrelor (3M) or PSB-0739 (25M) (*p<0.05 versus ADP alone; 
N=5). 
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Figure 5 Inhibition of adenylate cyclase reverses antagonistic action of ticagrelor on 
ADP-evoked Ca2+ responses in THP-1 cells. (A) Averaged (N=5) 3M ADP-evoked Ca2+ in 
the presence of vehicle (closed circles) or following adenylate cyclase inhibition with 300M 
SQ22536. (B)  Averaged (N=5) 3M ADP-evoked Ca2+ in the presence of vehicle (closed 
circles), 5M ticagrelor (open circles) or 5M ticagrelor plus 300M SQ22536 (closed 
squares). (C) ADP concentration-response curve (N=5) in the presence of vehicle (closed 
circles), 5M ticagrelor (open circles) or 5M ticagrelor plus 300M SQ22536 (closed 
squares). For all experiments, F ratio is the ratiometric measurement of intracellular Ca2+ 
using fura-2. * p<0.05. 
 
